Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

被引：0
|
作者：
Ying Hu [1 ]
Huimin Zou [2 ]
Yang Shen [3 ]
Qi Ni [4 ]
Yijun Li [1 ]
Hao Zhang [1 ]
Xianwen Chen [5 ]
Carolina Oi Lam Ung [2 ]
Hao Hu [2 ]
Yiming Mu [6 ]
机构：
[1] PLA General Hospital,Department of Endocrinology, First Medical Center of Chinese
[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[3] Peking University,School of Public Health
[4] Peking University,China Center for Health Development Studies
[5] Novo Nordisk (China) Pharmaceuticals Co.,Centre for Pharmaceutical Regulatory Sciences
[6] Ltd.,Department of Public Health and Medicinal Administration, Faculty of Health Sciences
[7] University of Macau,undefined
[8] University of Macau,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
Type 2 diabetes; Semaglutide; Dulaglutide; Cost-effectiveness analysis; China;
D O I：
10.1007/s13300-025-01716-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 929
页数：14
相关论文
共 50 条
  • [41] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Adie Viljoen
    Barrie Chubb
    Samuel J. P. Malkin
    Sasha Berry
    Barnaby Hunt
    Stephen C. Bain
    The European Journal of Health Economics, 2023, 24 : 895 - 907
  • [42] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Matthew Capehorn
    Nino Hallén
    James Baker-Knight
    Divina Glah
    Barnaby Hunt
    Diabetes Therapy, 2021, 12 : 537 - 555
  • [43] EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING
    Capehorn, M.
    Hallen, N.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S512 - S512
  • [44] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Capehorn, Matthew
    Hallen, Nino
    Baker-Knight, James
    Glah, Divina
    Hunt, Barnaby
    DIABETES THERAPY, 2021, 12 (02) : 537 - 555
  • [45] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes Response
    Arslanian, Silva A.
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1530 - 1531
  • [46] Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
    Chuang, L. H.
    Verheggen, B. G.
    Charokopou, M.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1127 - 1134
  • [47] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE
    Charokopou, M.
    Chuang, L.
    Verheggen, B.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [48] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [49] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    Applied Health Economics and Health Policy, 2022, 20 : 543 - 555
  • [50] COST-UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES REQUIRING TREATMENT WITH A GLP-1 RECEPTOR AGONIST
    Uranga, Garcia J.
    Jung, S.
    Dahaoui, Smeat
    VALUE IN HEALTH, 2022, 25 (12) : S160 - S160
12345